Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease

British Journal of Pharmacology

Volumn 161, Issue 2, 2010, Pages 271-287

  Duty, Susan ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

basal ganglia; group III mGlu receptors; metabotropic glutamate receptors; motor symptoms; neurodegeneration; Parkinson's disease; substantia nigra

Indexed keywords

(1,3,4) 1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; (3) 3 [(3 AMINO 3 CARBOXYPROPYL(HYDROXYL)PHOSPHINYL)HYDROXYMETHYL] 5 ITROTHIOPHENE; 3,4 DICARBOXYPHENYLGLYCINE; CIS 2 (3,5,DICHLORPHENYLCARBAMOYL)CYCLO HEXANECARBOXYLIC ACID; HALOPERIDOL; METABOTROPIC RECEPTOR AGONIST; N PHENYL 7 (HYDROXYLIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXAMIDE; N,N' DIBENZHYDRYL ETHANE 1,2 DIAMINE DIHYDROCHLORIDE; PHOSPHOSERINE; RESERPINE; UNCLASSIFIED DRUG;

BASAL GANGLION; CORPUS STRIATUM; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; BASAL GANGLIA; DIHYDROXYPHENYLALANINE; HUMANS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; RECEPTORS, METABOTROPIC GLUTAMATE; SYNAPTIC TRANSMISSION;

EID: 77954330278     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00882.x     Document Type: Review

References (105)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 : S1 S209.
2. Antonini A, Cilia R (2009). Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf 32 : 475 488.
3. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yanakaya B, Leenstra S et al. (2003). Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurol 17 : 2106 2118.
4. Austin PJ, Betts MJ, Broadstock M, O'Neill MJ, Mitchell SN, Duty S (2010). Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol 160 : 1741 1753.
5. Banerjee R, Starkov AA, Beal MF, Thomas B (2009). Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792 : 651 663.
6. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante A, Nicoletti F et al. (2006). Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26 : 7222 7229.
7. Benabid AL, Chabardes S, Mitrofanis J, Pollak P (2009). Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 8 : 67 81.
8. Besong G, Battaglia G, D'Onofrio M, Di Marco R, Ngomba RT, Storto M et al. (2002). Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J Neurosci 22 : 5403 5411.
9. Betts M, O'Neill M, Mitchell S, Duty S (2009). Allosteric modulation of group III mGlu receptor 4: a potential neuroprotective approach for the treatment of Parkinson's disease. Parkinsonism Relat Disord 15 (Suppl. 2 S121.
10. Beurrier C, Lopez S, Révy D, Selvam C, Goudet C, Lhérondel M et al. (2009). Electrophysiological and behavioural evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 23 : 3619 3628.
11. 2 receptors via the indirect striatal output pathway? Brain Res 753 : 163 175.
12. Blandini F, Porter RH, Greenamayre JT (1996). Glutamate and Parkinson's disease. Mol Neurobiol 12 : 73 94.
13. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62 : 63 88.
14. 123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 39 : 101 108.
15. Bradley SR, Standaert DG, Levey AI, Conn PJ (1999). Distribution of group III mGluRs in rat basal ganglia with subtype-specific antibodies. Ann N Y Acad Sci 868 : 531 534.
16. Carter CJ (1982). Topographical distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats. Neuropharmacology 21 : 379 383.
17. Cartmell J, Schoepp DD (2000). Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75 : 889 907.
18. Chaudhuri KR, Schapira AH (2009). Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8 : 464 474.
19. Conn PJ, Pin J-P (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37 : 205 237.
20. Conn PJ, Battaglia G, Marino MJ, Nicoletti F (2005). Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6 : 787 798.
21. Corti C, Aldegheri L, Somogyi P, Ferraguti F (2002). Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 110 : 403 420.
22. Cuomo D, Martella G, Barabino E, Platania P, Vita D, Madeo G et al. (2009). Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J Neurochem 109 : 1096 1105.
23. Dawson L, Chadha A, Megalou M, Duty S (2000). The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 129 : 541 546.
24. Department of Economic and Social Affairs (2009). World Population Ageing 2009. United Nations : New York. Available at: http://www.un.org/esa/ population/publications/WPA2009/WPA2009-WorkingPaper.pdf (accessed 12 June 2010)
25. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S et al. (1997). Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62 : 10 15.
26. Di Loreto S, Florio T, Scarnati E (1992). Evidence that non-NMDA receptors are involved in the excitatory pathway from the pedunculopontine region to nigrostriatal dopaminergic neurons. Exp Brain Res 89 : 79 86.
27. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD (2008). Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33 : 1603 1610.
28. Engers DW, Niswender CM, Weaver CD, Jadhav S, Menon UN, Zamorano R et al. (2009). Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem 52 : 4115 4118.
29. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goedt CG (2007). Levodopa-induced dyskinesia. Mov Disord 22 : 1379 1389.
30. Falk T, Zhang S, Sherman SJ (2009). Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Neurosci Lett 458 : 49 52.
31. Fearnley JM, Lees AJ (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 : 2283 2301.
32. Goudet C, Chapuy E, Alloui A, Acher F, Pinn J-P, Eschalier A (2008). Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 137 : 112 124.
33. Gu B, Zhang Y-D, Hu G (2003). A unilateral 6-hydroxydopamine lesion decreases the expression of metabotropic glutamate receptors in rat substantia nigra. Neurosci Lett 351 : 186 190.
34. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH et al. (2005). Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62 : 378 382.
35. Hirsch EC, Périer C, Orieux G, François C, Féger J, Yelnik J et al. (2000). Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci 23 : S78 S85.
36. Iacovelli L, Bruno V, Salvatore L, Melchiorri D, Gradini R, Caricasole A et al. (2002). Native group III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phopshatidylinositol-3-kinase pathways. J Neurochem 82 : 216 223.
37. Iacovelli L, Capobianco L, Iula M, Di Giorgi Gerevini V, Picascia A, Blahos J et al. (2004). Regulation of mGlu4 metabotropic glutamate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2). Mol Pharmacol 65 : 1103 1110.
38. Iribe Y, Moore K, Pang KC, Tepper JM (1999). Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurones in vitro. J Neurophysiol 82 : 925 933.
39. Janca A (2002). Parkinson's disease from WHO perspective and a public health point of view: short survey. Parkinsonism Relat Disord 9 : 3 6.
40. Jenner P (2008). Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9 : 665 677.
41. Jiang Q, Yan Z, Feng J (2006). Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism. J Neurosci 26 : 4318 4328.
42. Johnston T, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM (2010). Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 333 : 865 873.
43. Kew JN (2004). Postiive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 104 : 233 244.
44. Kita H, Kitai ST (1987). Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 260 : 435 452.
45. Klak K, Palucha A, Brański P, Sowa M, Pilc A (2007). Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 32 : 169 172.
46. Konieczny J, Wardas J, Kuter K, Pilc A, Ossowska K (2007). The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1- aminocyclopentane-1,3,4-tricarboxylic acid on the parkinsonian like akinesia and striatal proenkephalin and prodynorphin expression in rats. Neuropharmacology 145 : 611 620.
47. Kornhuber J, Weller M (1997). Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41 : 135 144.
48. Kosinski CM, Bradley SR, Conn PJ, Levey AI, Landwehrmeyer GB, Penney JB Jr. et al. (1999). Localisation of metabotropic glutamate 7 mRNA and mGluR7a protein in the rat basal ganglia. J Comp Neurol 415 : 266 284.
49. Lang AE, Lozano AM (1998). Parkinson's disease. First of two parts. N Engl J Med 339 : 1044 1053.
50. Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M (2007). Targeting group III metabotropic glutamate receptors produces complex behavioural effects in rodent models of Parkinson's disease. J Neurosci 27 : 6701 6711.
51. Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P et al. (2008). Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 55 : 483 490.
52. Lozano AM (2003). Surgery for Parkinson's disease, the five W's: why, who, what, where, and when. Adv Neurol 91 : 303 307.
53. MacInnes N, Duty S (2008). Group III metabotropic glutamate receptors act as hetero-receptors modulating GABA release in the globus pallidus in vivo. Eur J Pharmacol 580 : 95 99.
54. MacInnes N, Messenger MJ, Duty S (2004). Activation of group III metaobotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol 141 : 15 22.
55. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W et al. (2003). (-)-PHCCC, a positive allosteric modulator of mGlu receptor4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45 : 895 906.
56. Marabese I, de Novellis V, Palazzo E, Scafuro MA, Vita D, Rossi F et al. (2007). Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice. Neuropharmacology 52 : 253 262.
57. Marino MJ, Williams DL Jr., O'Brien JA, Valenti O, McDonald TP, Clements MK et al. (2003). Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A 100 : 13668 13673.
58. Marsden CD, Parkes JD (1977). Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 : 345 349.
59. McNaught KS, Jenner P (1999). Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 73 : 2469 2476.
60. McNaught KS, Jenner P (2000). Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem Pharmacol 60 : 979 988.
61. Messenger MJ, Dawson LG, Duty S (2002). Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract. Neuropharmacology 43 : 261 271.
62. Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S et al. (2005). A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A 102 : 18712 18717.
63. Morrish PK, Rakshi JS, Bailey DL, Sawler GV, Brooks DJ (1998). Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 : 314 319.
64. Murray TK, Messenger MJ, Ward MA, Woodhouse S, Osborne DJ, Duty S et al. (2002). Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73 : 455 466.
65. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q et al. (2008a). Discovery, characterisation and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 74 : 1345 1358.
66. Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H et al. (2008b). Positive allosteric modulators of the metabotropic receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolol[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett 18 : 5626 5630.
67. Obeso JA, Rodriguez-Orez MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N et al. (2000). Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 : S8 S19.
68. Obeso JA, Rodriguez-Orez MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C et al. (2008). Functional organization of the basal ganglia: therapeutic implications for the treatment of Parkinson's disease. Mov Disord 23 : S548 S559.
69. Ossowska K, Pietraszek M, Wardas J, Wolfarth S (2004). Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist. Pol J Pharmacol 56 : 295 304.
70. Palucha A, Tatarczyńska E, Brański P, Szewczyk B, Wierońska JM, Klak K et al. (2004). Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 46 : 151 159.
71. Palucha-Poniewiera A, Klodzińska A, Stachowicz K, Tokarski K, Hess G, Schann S et al. (2008). Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55 : 517 524.
72. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT (2005). Rotenone model of Parkinson's disease: multiple brain mitochondria dysfunctions after short-term systemic rotenone intoxication. J Biol Chem 280 : 42026 42035.
73. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13 : 1102 1107.
74. Pelkey KA, Lavezzari G, Racca C, Roche KW, McBain CJ (2005). mGlu receptor7 is a metaplastic switch controlling bidirectional plasticity of feedforward inhibition. Neuron 46 : 89 102.
75. Piallat B, Benazzouz A, Benabid AL (1996). Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8 : 1408 1414.
76. Pisani A, Calabresi P, Centonze D, Bernardi G (1997). Activation of group III metabotropic glutamate receptors depresses glutamatergic transmission at corticostriatal synapse. Neuropharmacology 36 : 845 851.
77. Ren Y, Liu W, Jiang H, Jiang Q, Feng J (2005). Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 280 : 34105 34112.
78. Rodriguez MC, Obeso JA, Olanow CW (1998). Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44 : S175 S188.
79. Rodriguez JP, Walters SE, Watson P, Stell R, Mastaglia FL (2007). Globus pallidus stimulation in advanced Parkinson's disease. J Clin Neurosci 14 : 208 215.
80. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ (2000). Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 88 : 427 435.
81. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA (2009). Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330 : 227 235.
82. Saugstad JA, Segerson TP, Westbrook GL (1996). Metabotropic glutamate receptors activate G-protein-coupled inwardly rectifying potassium channels in Xenopus oocytes. J Neurosci 16 : 5979 5985.
83. Schulz JB (2007). Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism Relat Disord 13 : S306 S308.
84. Smith Y, Hazrati LN, Parent A (1990). Efferent projections of the subthalamic nucleus in the squirrel monkey as studied by the PHA-L anterograde tracing method. J Comp Neurol 294 : 306 323.
85. Smith Y, Bevan MD, Shink E, Bolam JP (1998). Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 86 : 353 387.
86. Taylor DL, Diemel LT, Pocock JM (2003). Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 23 : 2150 2160.
87. Testa CM, Standaert DG, Young AB, Penney JB Jr. (1994). Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 14 : 3005 3018.
88. Thomas NK, Wright RA, Howson PA, Kingston AE, Schoepp DD, Jane DE (2001). (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 40 : 311 318.
89. Trombley PQ, Westbrook GL (1992). L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor. J Neurosci 12 : 2043 2050.
90. Valenti O, Marino MJ, Wittmann M, Lis E, DiLella AG, Kinney GG et al. (2003). Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci 23 : 7218 7226.
91. Valenti O, Mannaioni G, Seabrook GR, Conn PJ, Marino MJ (2005). Group III metabotropic glutamate receptor-mediated modulation of excitatory transmission in the rodent substantia nigra pars compacta dopamine neurons. J Pharmacol Exp Ther 313 : 1296 1304.
92. Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT (2005). Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 22 : 1799 1806.
93. Vernon AC, Zbarsky V, Datla KP, Dexter DT, Croucher MJ (2007). Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4- phosphonobutyric acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Pharmacol Exp Ther 320 : 397 409.
94. Vila M, Marin C, Ruberg M, Jimenez A, Raisman-Vozari R, Agid Y et al. (1999). Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J Neurochem 73 : 344 352.
95. Whitton PS (2007). Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150 : 963 976.
96. Wigmore MA, Lacey MG (1998). Metabotopic glutamate receptors depress glutamate-mediated synaptic input to rat midbrain dopamine neurones in vitro. Br J Pharmacol 123 : 667 674.
97. Williams R, Niswender CM, Luo Q, Le U, Conn PJ, Lindsley CW (2009). Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: challenges in hit-to-lead. Bioorg Med Chem Lett 19 : 962 966.
98. Wittmann M, Marino M, Bradley SR, Conn PJ (2001). Activation of group III mGluRs inhibits GABA-ergic and glutamatergic transmission in the substantia nigra pars reticulata. J Neurophysiol 85 : 1960 1968.
99. Wittmann M, Marino M, Conn PJ (2002). Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther 302 : 433 441.
100. Yamamoto N, Soghomonian JJ (2009). Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by L-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 163 : 1171 1180.
101. Yao HH, Ding JH, Zhou F, Wang F, Hu LF, Sun T et al. (2005). Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes. J Neurochem 92 : 948 961.
102. You Z-B, Herrera-Marschitz M, Pettersson E, Nylander I, Goiny M, Shou HZ et al. (1996). Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity. Neuroscience 74 : 793 804.
103. Zahodne LB, Fernandez HH (2008). Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 25 : 665 682.
104. Zhang HM, Chen SR, Pan HL (2009). Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain. Neuroscience 158 : 875 884.
105. Zhou F, Yao H-H, Wu J-Y, Yang Y-J, Ding J-H, Zhang J et al. (2006). Activation of group II/III metabotropic glutamate receptors attenuates LPS-induced astroglial neurotoxicity via promoting glutamate uptake. J Neurosci Res 84 : 268 277.